Pages that link to "Q33188291"
Jump to navigation
Jump to search
The following pages link to Ethics of phase 1 oncology studies: reexamining the arguments and data (Q33188291):
Displaying 50 items.
- The myth of equipoise in phase 1 clinical trials (Q24569794) (← links)
- Phase I trials of antitumour agents: fundamental concepts (Q26865346) (← links)
- Pharmacodynamic biomarkers for molecular cancer therapeutics (Q28278381) (← links)
- Vulnerability in clinical research with patients in pain: a risk analysis (Q30431269) (← links)
- Adolescent perspectives on phase I cancer research (Q30531481) (← links)
- Sham surgery controls in Parkinson's disease clinical trials: views of participants. (Q30541211) (← links)
- Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital (Q33263052) (← links)
- Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience (Q33399986) (← links)
- Quality assessment of phase I dose-finding cancer trials: proposal of a checklist (Q33644414) (← links)
- Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? (Q33819306) (← links)
- Unrealistic optimism in early-phase oncology trials (Q34163982) (← links)
- Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. (Q34251038) (← links)
- Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception? (Q34560093) (← links)
- Hope and persuasion by physicians during informed consent (Q34682676) (← links)
- Threading the cloak: palliative care education for care providers of adolescents and young adults with cancer (Q35148951) (← links)
- Development and testing of a tool to assess patient preferences for phase I clinical trial participation (Q35761580) (← links)
- Extending clinical equipoise to phase 1 trials involving patients: unresolved problems (Q35788038) (← links)
- Comparison of enrollees and decliners of Parkinson disease sham surgery trials (Q35881926) (← links)
- American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment (Q35894574) (← links)
- An approach to evaluating the therapeutic misconception (Q35989895) (← links)
- Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements (Q36014074) (← links)
- Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials (Q36192000) (← links)
- Communication and informed consent in phase 1 trials: a review of the literature. (Q36457881) (← links)
- Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs (Q36621961) (← links)
- Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? (Q36736782) (← links)
- The ethical use of mandatory research biopsies (Q36783493) (← links)
- The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials (Q36818341) (← links)
- Risks and benefits associated with novel phase 1 oncology trial designs (Q36880257) (← links)
- Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations (Q36984204) (← links)
- Running an ethical trial 60 years after the Nuremberg Code (Q37022475) (← links)
- Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent (Q37071723) (← links)
- Phase 0 clinical trials: conceptions and misconceptions (Q37184280) (← links)
- First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless (Q37217591) (← links)
- Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? (Q37222606) (← links)
- Palliative care in adolescents and young adults with cancer (Q37583165) (← links)
- Strategies to minimize risks and exploitation in phase one trials on healthy subjects (Q37620111) (← links)
- Manufacturing mistrust: issues in the controversy regarding foster children in the pediatric HIV/AIDS clinical trials (Q37622120) (← links)
- Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers (Q37636655) (← links)
- Is Participation in Cancer Phase I Trials Really Therapeutic? (Q37660474) (← links)
- Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death (Q37686819) (← links)
- Mindsets, informed consent, and research (Q37700964) (← links)
- Recommendations for enhancing clinical trials education: a review of the literature (Q37791483) (← links)
- Influence of early phase clinical trial enrollment on patterns of end-of-life care for children with advanced cancer. (Q38647531) (← links)
- Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role (Q38834374) (← links)
- Ethical considerations and challenges in first-in-human research (Q38874665) (← links)
- Rethinking risk assessment for emerging technology first-in-human trials (Q38974025) (← links)
- Precision medicine needs randomized clinical trials (Q39124225) (← links)
- Evaluation of factors that motivate participants to consent for non-therapeutic trials in India (Q39454350) (← links)
- Do phase 1 patients have greater needs for palliative care compared with other cancer patients? (Q39867384) (← links)
- Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? (Q40025547) (← links)